CAR-T therapy is recognized as Chimeric Antigen Receptor Therapy. It is an immunotherapy used for the cancer treatment. In this therapy, T cells from patient body are isolated & inserted in the CAR gene therefore; the gene for specific receptor binds to the certain protein on the patient’s cancer cells.
According to study, “CAR-T Therapy Market Global Report 2020-30” the key companies operating in the global CAR-T therapy market are Aleta BioTherapeutics, Bellicum Pharmaceuticals, Inc., Allogene Therapeutics, Celgene Corporation, Anixa Biosciences, Inc., Cartesian Therapeutics, Inc., Attars Biotherapeutics, Cytovia Therapeutics, Autolus Therapeutics, plc, CRISPR Therapeutics, BioNTech, Eureka Therapeutics, Inc., bluebird bio, EXUMA Biotech Corp., Carina Biotech, Fate Therapeutics, Inc, CARsgen Therapeutics, Janssen Biotech, Inc., Cellectis, Creative Biolabs, Celularity, Inc., iCell Gene Therapeutics, Celyad Oncology, Nanjing Legend Biotechnology Co., Ltd., DiaCarta, Inc., Minerva Biotechnologies Corporation, Formula Pharmaceuticals, Inc., Novartis International, AG, Gilead Sciences, Inc., Poseida Therapeutics, Inc., Juno Therapeutics, PeproMene Bio, Inc., JW Therapeutics, Co., Ltd., Sorrento Therapeutics, Inc., Kite Pharma, Inc., ProMab Biotechnologies, Inc., MaxCyte, Inc., Prescient Therapeutics, Mustang Bio, Inc., Tmunity Therapeutics, Inc., Noile-Immune Biotech, Tessa Therapeutics, Pvt. Ltd., Empirica Therapeutics, CARTherics,Oxford Biomedica plc., Ziopharm Oncology, Inc., Precigen, Inc., TC Biopharm, Precision Biosciences, T-CURX, Protheragen, Xyphos Biosciences, Inc. and Wugen.
Based on targeted antigen, CAR-T therapy market is segmented as CD 19, CD 20, CD22, CD30, CD33, GD2, HER1, HER2, Meso, Egfrvlll and others. Based on therapeutic application, market is segmented as Non Hodgkin Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Pancreatic Cancer, Multiple Myeloma, Acute Myeloid Leukemia, Hepatocellular, Neuroblasta, Breast Cancer, Colorectal Cancer, Carcinoma, and others.
The CAR-T therapy market is driven by increase in incidence of cancer, followed by rise in number of patients showing response failure to alternative treatments, change in disease patterns, increase in awareness about healthcare & wellness, rise in volume of implementation of the T-Cell therapies in various cancer research centers and increase in government support. However, rise in concerns associated with the side effects of the cell therapy and other neurological problems may impact the market. Moreover, growth in research for cell therapy in cancer and increase in government initiatives for improving health care infrastructure are key opportunities for market.
Based on geography, the North-American region holds major share in global CAR-T therapy market owing to favorable policies of reimbursement, early availability of products of CAR-T cell therapy, rise in incidences of severe lymphoblastic leukemia, and increase in per capita expenditure on healthcare in the region. The Asian-Pacific and European regions are estimated to exhibit substantial growth rate due to presence of a large number of clinical pipeline drugs during the forecast period. It is likely that future of the global market will be optimistic on account of increase in the occurrences of hematologic cancer such as lymphoma, leukemia, and multiple myeloma during the forecast period. The worldwide CAR-T therapy market was valued at US $611.31 million in 2019 and it is likely to grow at a CAGR of 51.10% and reach US $3,186.54 million by 2023.
For More Information, Click on the Link Below:-
Ankur Gupta, Head Marketing & Communications